Sanofi inked a research collaboration and license agreement with Stockholm, Sweden-based Salipro Biotech, whose proprietary platform enables researchers to improve workflows for developing therapeutic antibodies or small molecules that target membrane proteins.
The scholarships will prioritize students from underrepresented groups, who have overcome disadvantages or are first generation to attend college. The research collaboration aims to develop new methods for delivering therapies to patients.
The FDA’s Center for Drug Evaluation and Research issued its briefing documents arguing for the market withdrawal of Covis Pharma’s Makena. The agency will discuss the drug on Oct. 17-19.
Bristol Myers Squibb entered two separate research collaboration and licensing deals, one with San Francisco-based SyntheX and the second with London’s Autolus Therapeutics.
Pfizer signaled its interest in longevity research through a new partnership -and a $500,000 investment – in a decentralized drug development program driven by VitaDAO.
AstraZeneca may not stay in the vaccine business in the long run, its CEO told Reuters on Tuesday, showing how quickly fortunes have changed for the drugmaker that produced one of the first COVID-19 shots but has since lost out to rivals.
Researchers have found that decay of tissues after death can be halted and cell functions restored based on early experiments in pigs that may eventually help increase the number of transplantable human organs.
Marengo Therapeutics and Ipsen announced Monday that they have entered into a strategic, multi-year partnership to usher two of Marengo’s precision T cell immuno-oncology candidates into the clinic.
Thursday morning, Takeda reported its quarterly sales ending June 30, 2022. The company reported a 2.4% increase in revenue for the quarter from the same period in 2021, as well as changes to its pipeline, including a decision to drop a cancer therapeutic developed with Turnstone Biologics.
Beset by clinical holds and the termination of its former company head, CytoDyn Inc. has tapped Cyrus Arman as its new president and he is expected to take over the reins of the company as chief executive officer and be added to the board of directors within six months.